Previous Close | 12.70 |
Open | 12.15 |
Bid | 12.35 x N/A |
Ask | 13.10 x N/A |
Day's Range | 12.15 - 12.15 |
52 Week Range | 10.16 - 15.72 |
Volume | |
Avg. Volume | 5 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Mar 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Lannion, 3 May 2024 – 7:30 am LUMIBIRD MEDICAL OBTAINS CE MARKING FOR C.DIAG®, A PLATFORM TO HELP DIAGNOSE DRY EYE The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, announces the launch by Lumibird Medical of C.DIAG®, a new-generation dry eye diagnostic aid platform incorporating Artificial Intelligence. This Europe-wide launch follows the CE marking certified by LNE-GMED on 30 April 2024. This new product completes the C.SUITETM offering with diagnosis, treat
Lannion, 05/04/2024 - 17h45 LUMIBIRD: PUBLICATION OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT LUMIBIRD announces that it has filed its 2023 Universal Registration Document containing the annual financial report with the Autorité des Marchés Financiers (AMF) on 05 April 2024, under number D.24-0239. The document is available : at LUMIBIRD's head office: 2 rue Paul Sabatier, 22 300 Lannion.on the company's website: www.lumibird.com ("Regulated information" sec
Lannion, March 25, 2024– 5:45pm LUMIBIRD: ACCESS TO PREPARATORY DOCUMENTS FOR THE COMBINED GENERAL MEETING ON APRIL 29, 2024 LUMIBIRD’s shareholders are informed that they are invited to take part in the Combined General Meeting to be held on Friday, April 29th, 2024 from 2:00pm (CET) at 15 rue du Zéphyr, ZA de Courtabœuf, 91140 VILLEJUST- France. The meeting notice containing the agenda, the text of the resolutions and the main conditions for taking part in and voting at the General Meeting was